Incorporating brachytherapy in standard treatment protocols for elderly cervical cancer patients has the potential to improve treatment outcomes, according to a review study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Stratifying ovarian cancer patients with gene expression molecular subtypes (GEMS) enables the identification of AXL in mesenchymal subtype ovarian cancer, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Monotherapy using the immune checkpoint inhibitors anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may not be sufficient for ovarian cancer, according to data presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
Chemotherapy is associated with better overall survival (OS) in patients with advanced angiosarcoma, though only a select number receive this treatment, according to findings from the first collaborative study by the Asian Sarcoma Consortium (ASC).
Nivolumab has emerged as a potential therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based therapy, based on results of a subgroup analysis of Asian patients in the CheckMate 141* trial.
Palbociclib, in combination with letrozole, significantly improves progression-free survival (PFS) in Asian postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer compared with letrozole alone, according to a sub-analysis of Asian patients enrolled in the PALOMA-2* study presented at the recent European Society for Medical Oncology Asia 2016 Congress (ESMO Asia 2016) in Singapore.
Ceritinib shows clinically meaningful activity in advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), producing a rapid, durable response rate and improvements in patient-reported outcomes in individuals who have progressed on crizotinib, according to two studies presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held in Singapore.
During the period between 1999 and 2008, there have been major changes in the preferences of breast cancer treatment in China, according to an expert who spoke at the recently concluded European Society of Medical Oncology (ESMO) Asia 2016 Congress.
Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).